Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 4/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | WNT3A | P56704 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.37 |
| ▸ | CES1 | P23141 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7832355 | 0.89 | NPC1 (0.47) | RAB9ANPC1KMT2ACTNNB1MEN1 | |
| SCHEMBL7568236 | 0.85 | CES2 (0.43) | RAB9ANPC1KMT2AMEN1L3MBTL1 | |
| SCHEMBL7832652 | 0.84 | GSK3B (0.44) | RAB9ANPC1KMT2AHSD11B1MEN1 | |
| SCHEMBL7850769 | 0.84 | RAB9A (0.55) | RAB9ANPC1KMT2AHSD11B1MEN1 | |
| SCHEMBL6168851 | 0.84 | RAB9A (0.47) | RAB9ANPC1PTPN1KMT2AMEN1 | |
| SCHEMBL7833284 | 0.84 | KMT2A (0.48) | RAB9ANPC1KMT2ACTNNB1MEN1 | |
| SCHEMBL7622865 | 0.82 | TDP1 (0.50) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7839557 | 0.82 | NPC1 (0.51) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL7846518 | 0.78 | CES2 (0.43) | RAB9ANPC1KMT2AHSD11B1MEN1 | |
| SCHEMBL7746397 | 0.78 | HDAC1 (0.43) | RAB9ANPC1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1466897-B1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | DIPHARMA FRANCIS SRL (IT) | 2008-12-17 | — | — | EP | disclosed |
| EP-1466897-A1 | Process for the preparation of organic compounds containing a sulfinyl or sulfonyl group in the presence of epsilon-phthalimidoperhexanoic acid | Dipharma S.p.A. (IT) | 2004-10-13 | — | — | EP | disclosed |
| US-6670365-B1 | Treatment of inflamation and/or cyclooxygenase-mediated diseases, reduced ulcerogenic effects; 2-phenyl-3-(4-methylsulfonylphenyl)imidazo(1,2-a)pyrimidine | LABORATORIOS S.A.L.V.A.T., S.A. (ES) | 2003-12-30 | — | — | US | disclosed |
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
| EP-1104762-B1 | SUBSTITUTED IMIDAZO[1,2A]AZINES AS SELECTIVE INHIBITORS OF COX-2 | S A L V A T LAB SA (ES) | 2002-09-18 | — | — | EP | disclosed |
| EP-0772601-B1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-09-18 | — | — | EP | disclosed |
| US-6426360-B1 | ANTIARTHRITIC AGENTS | G D SEARLE & CO. | 2002-07-30 | — | — | US | disclosed |
| EP-0699192-B1 | SUBSTITUTED OXAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | SEARLE & CO (US) | 2002-07-24 | — | — | EP | disclosed |
| EP-1211244-A2 | 4,5-substitued imidazolyl compounds for the treatment of inflammation | G.D. Searle & Co. (US) | 2002-06-05 | — | — | EP | disclosed |
| US-6294568-B1 | ANTIINFLAMMATORY AGENTS AND ANTITUMOR AGENTS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENTS AND COX2 ENZYME INHIBITORS | NISSIN FOOD PRODUCTS CO., LTD. (JP) | 2001-09-25 | — | — | US | disclosed |
| US-5686470-A | 2, 3-substituted pyridines for the treatment of inflammation | WEIER RICHARD M (US) | 1997-11-11 | — | — | US | disclosed |
| US-5668161-A | Substituted thiazoles for the treatment of inflammation | G.D. SEARLE & CO. (US) | 1997-09-16 | — | — | US | disclosed |
| EP-0772606-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| EP-0772601-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1997-05-14 | — | — | EP | disclosed |
| US-5620999-A | ANTIARTHRITIC, ANALGESIC AND ANTIPYRATIC AGENT | G.D. SEARLE & CO. | 1997-04-15 | — | — | US | disclosed |
| WO-1996036617-A1 | SUBSTITUTED OXAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-11-21 | — | — | WO | disclosed |
| WO-1996003392-A1 | SUBSTITUTED THIAZOLES FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| WO-1996003387-A1 | 4,5-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | G.D. SEARLE & CO. (US) | 1996-02-08 | — | — | WO | disclosed |
| US-5082974-A | 3-HALOGENO-2,3-DIPHENYLACRYLALDEHYDE DERIVATIVES, PROCESS FOR PREPARING THE SAME AND A PHARMACEUTICAL COMPOSITION FOR TREATING HYPERLIPIDEMI | OTSUKA PHARACEUTICAL FACTORY, INC. (JP) | 1992-01-21 | — | — | US | disclosed |
| EP-0424541-A1 | 3-HALOGENO-2,3-DIPHENYLACRYLALDEHYDE DERIVATIVE, METHOD OF PRODUCTION THEREOF AND CURING AGENT FOR HYPERLIPIDEMIA | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | RAB9A 3539/4885NPC1 3307/4885PTPN1 702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.